Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxycycline for Filarial Lymphedema (LeDoxy-India)
NCT02929121Phase 3Completed
- Sponsor
- Task Force for Global Health
- Start
- Jan 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of doxycycline in lymphedema and lymphatic filariasis (LF), sponsored by Task Force for Global Health. Primary endpoint: Change in Lymphedema Grade at 24 months. Started Jan 2019; status: completed.
02
Drugs
doxycycline
03
Conditions
lymphedemalymphatic filariasis (LF)
Beyond the preview
Go deeper on NCT02929121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02929121.